X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 30 07:02 ET
Express News | HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
BenzingaApr 30 06:52 ET
X4 Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 334.78% HC Wainwright & Co. $3 → $5 Maintains Buy 03/22/2024 160.87% HC Wainwright & Co. → $3 R
BenzingaApr 30 06:51 ET
Buy Rating Affirmed for X4 Pharmaceuticals' Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy
TipRanksApr 30 06:20 ET
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.(Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it w
X4 PharmicalsApr 30 00:00 ET
PANTHERx® Rare Partnering With X4 Pharmaceuticals Inc. for the Distribution of XOLREMDITM (Mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients With WHIM Syndrome
PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4...
PR NewswireApr 29 12:28 ET
Express News | X4 Pharmaceuticals Inc - Set Wholesale Acquisition Cost for Xolremdi on an Annual Basis to $496,400 for Patients Greater Than 50 Kilograms
ReutersApr 29 08:32 ET
UPDATE 1-US FDA Approves X4 Pharmaceuticals' Therapy for Immunodeficiency Disease
Yahoo FinanceApr 29 06:47 ET
X4 Pharmaceuticals Launches XOLREMDI With FDA Approval
TipRanksApr 29 06:42 ET
Express News | X4 Pharmaceuticals Shares Rise 12.5% Premarket After US FDA Approves Co's Immunodeficiency Drug
ReutersApr 29 06:39 ET
Express News | X4 Pharmaceuticals Shares Are Trading Higher After the FDA Approved the Company's Xolremdi (Mavorixafor) for WHIM Syndrome
BenzingaApr 29 06:34 ET
Express News | FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And Lymphocytes
BenzingaApr 29 06:32 ET
Express News | X4 Pharmaceuticals Announces FDA Approval of Xolremdi™ (Mavorixafor) Capsules, First Drug Indicated in Patients With Whim Syndrome
ReutersApr 29 06:30 ET
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI (Mavorixafor) Capsules, First Drug Indicated in Patients With WHIM Syndrome
XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric
X4 PharmicalsApr 29 00:00 ET
12 Health Care Stocks Moving In Friday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.
BenzingaApr 26 12:31 ET
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Market Cap Decline of US$42m May Not Have as Much of an Impact on Institutional Owners After a Year of 7.0% Returns
Yahoo FinanceApr 11 10:15 ET
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024,
GlobeNewswireApr 2 16:05 ET
X4 Pharmaceuticals Updates Corporate Presentation Online
TipRanksApr 1 09:32 ET
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that managemen
X4 PharmicalsApr 1 00:00 ET
X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence
TipRanksMar 23 02:01 ET
No Data
No Data